Efficacy and influencing factors of 3-N-Butylphthalide-trazodone combination in managing post-ischemic stroke depression

Table 1 General patient data, n (%)

Indicators	Reference group (n = 56)	Research group (n = 66)	χ2/t	P value
Age (years)	59.96 ± 6.89	57.67 ± 8.68
Male	35 (62.50)	40 (60.61)	0.046	0.830
Body mass index (kg/m2)	23.34 ± 2.27	22.74 ± 2.36	1.424	0.157
Stroke course (day)	20.36 ± 5.69	22.36 ± 6.27	1.831	0.070
Infarction site			0.529	0.767
Cortical and subcortical	28 (50.00)	35 (53.03)
Brainstem	15 (26.79)	14 (21.21)
Cerebellum	13 (23.21)	17 (25.76)
Hypertension	15 (26.79)	20 (30.30)	0.183	0.669
Diabetes	23 (41.07)	19 (28.79)	2.025	0.155
Hyperlipidaemia	11 (19.64)	15 (22.73)	0.172	0.679

Table 2 Curative effect analysis, n (%)

Indicators	Reference group (n = 56)	Research group (n = 66)	χ2	P value
Significantly effective	25 (44.64)	39 (59.09)
Effective	17 (30.36)	20 (30.30)
Ineffective	14 (25.00)	7 (10.61)
Overall effectiveness	42 (75.00)	59 (89.39)	4.405	0.036

Table 3 Safety analysis, n (%)

Indicators	Reference group (n = 56)	Research group (n = 66)	χ2	P value
Nausea	0 (0.00)	2 (3.03)
Celialgia	1 (1.79)	1 (1.52)
Headache	1 (1.79)	0 (0.00)
Drowsiness	3 (5.36)	0 (0.00)
Total	5 (8.93)	3 (4.55)	0.950	0.330

Table 4 Determinants of patients' curative effects by univariate analysis, n (%)

Indicators	Ineffective group (n = 21)	Effective group (n = 101)	χ2	P value
Age (years)			1.107	0.293
< 60	9 (42.86)	56 (55.45)
≥ 60	12 (57.14)	45 (44.55)
Male	12 (57.14)	63 (62.38)	0.201	0.654
Body mass index (kg/m2)			0.164	0.685
< 23	11 (52.38)	48 (47.52)
≥ 23	10 (47.62)	53 (52.48)
Stroke course (day)			1.055	0.304
< 20	7 (33.33)	46 (45.54)
≥ 20	14 (66.67)	55 (54.46)
Infarction site			0.332	0.847
Cortical and subcortical	10 (47.62)	53 (52.48)
Brainstem	6 (28.57)	23 (22.77)
Cerebellum	5 (23.81)	25 (24.75)
Hypertension	7 (33.33)	28 (27.72)	0.268	0.605
Diabetes	10 (47.62)	32 (31.68)	1.956	0.162
Hyperlipidaemia	8 (38.10)	18 (17.82)	4.261	0.039
NIHSS (points)			1.418	0.234
< 16	6 (28.57)	43 (42.57)
≥ 16	15 (71.43)	58 (57.43)
Barthel Index (points)			0.391	0.532
< 48	13 (61.90)	55 (54.46)
≥ 48	8 (38.10)	46 (45.54)
HAMD17 (points)			3.103	0.078
< 16	7 (33.33)	55 (54.46)
≥ 16	14 (66.67)	46 (45.54)
5-HT (ng/mL)			4.989	0.026
< 60	13 (61.90)	36 (35.64)
≥ 60	8 (38.10)	65 (64.36)
DA (ng/mL)			7.112	0.008
< 122	15 (71.43)	40 (39.60)
≥ 122	6 (28.57)	61 (60.40)
NE (ng/mL)			1.706	0.192
< 20	12 (57.14)	42 (41.58)
≥ 20	9 (42.86)	59 (58.42)
Medication regimen			4.405	0.036
3-N-Butylphthalide + Trazodonee	7 (33.33)	59 (58.42)
Trazodone	14 (66.67)	42 (41.58)

NIHSS: National Institutes of Health Stroke Scale; HAMD17: 17-item Hamilton Depression Rating Scale; 5-HT: 5-hydroxytryptamine; DA: Dopamine; NE: Norepinephrine.

Table 5 Predictors of patients’ curative effects by multivariate modeling

Variable	β	SE	Wald	P value	OR	95%CI
Hyperlipidaemia	1.394	0.602	5.369	0.020	4.030	1.240-13.102
5-HT (ng/mL)	-1.117	0.556	4.039	0.044	0.327	0.110-0.973
DA (ng/mL)	-1.592	0.589	7.315	0.007	0.203	0.064-0.645
Medication regimen	1.331	0.571	5.444	0.020	3.786	1.237-11.583

5-HT: 5-hydroxytryptamine; DA: Dopamine.